MASH / MASLD

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The month in review spotlights coverage of the anniversary of resmetirom’s FDA approval and research in autoimmune hepatitis, HBV vaccination, and MASLD.

Patients with celiac disease had a 2-fold greater risk of developing a chronic liver disease and experiencing major adverse liver outcomes.

In the RADIcAL-1 trial, mpMRI with LiverMultiScan reduced liver biopsies, led to fewer specialist consultations, and improved MASLD diagnosis rates.

Daily screen time exceeding 5 hours was associated with a greater risk of hepatic steatosis in adolescents, partially mediated by BMI.

Findings suggest cardiometabolic risk factors, diet, exercise, and social determinants of health are associated with HRQoL and fibrosis in MASLD.

ChatGPT offered valuable individualized nutritional recommendations for MASLD management, but they did not fully align with established guidelines.

The hepatology month in review spotlights HCPLive’s coverage of hepatic drug development and research about GLP-1 RAs, viral hepatitis, and MASH.

Stine explains key components of a new multidisciplinary MASLD care model and how it improves upon preexisting models.

Stine explains the continued need for diet and exercise in MASH and the importance of a multidisciplinary approach to treating these patients.

Positive 2-year results from the open-label compensated MASH cirrhosis arm of the MAESTRO-NAFLD-1 trial highlight resmetirom’s impact on liver stiffness.

Despite decreasing death rates, an analysis of GBD 2021 data highlights the increasing incidence of cirrhosis and other chronic liver diseases.

The analysis of US healthcare claims data suggests noninvasive methods are being used more often than liver biopsies for the diagnosis of MASH.

The multidisciplinary care model included 7 co-located specialists who aided patient education, lifestyle intervention, and drug therapy strategies for MASH.

The analysis of NHANES data found 11.3% of adolescents have suspected MASLD. Estimates were greater for those with elevated ALT.

Lee explains study findings suggesting MetALD classification should be based on ≥ 3 cardiometabolic risk factors rather than just alcohol intake.

GLP-1 RA use was associated with a lower risk of major cardiovascular events, clinically significant portal hypertension, and all-cause mortality in MASLD.

Laique reviews data supporting the use of metabolic surgery in patients with obesity and cirrhotic MASH.

Laique emphasizes the unmet needs for patients with cirrhotic MASH who are not eligible for resmetirom and what role metabolic surgery may play in their care.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

Greater magnesium depletion scores were longitudinally linked to increased risks for all-cause and CVD mortality in patients with MASLD or MetALD.

Although FIB-4, ELF, and VCTE LSM performance did not vary significantly by patient characteristics, threshold adjustment was needed.

Findings suggest MASLD, especially with diabetes, overweight, or hypertension, is associated with significant fibrosis in patients with HCV.

Compared with nonsurgical treatment, metabolic surgery was associated with reduced risks of incident MALO and progression to decompensation.

Preliminary topline week 96 results showed statistically significant reversal of MASH compensated cirrhosis with efruxifermin in complete and ITT analyses.